Healthark

As AI systems become more autonomous, monitoring whether an API request succeeds is no longer enough. In the agentic era, large language models can reason, call external tools, and make decisions across complex workflows, making reliability, cost control, and governance critical for production success.

LLM observability provides the visibility organizations need to understand how AI behaves in real-world environments. It enables teams to detect hallucinations, monitor production drift, control token costs, trace every model interaction, and identify performance bottlenecks before they affect users. Without observability, issues such as inaccurate outputs, escalating infrastructure costs, and inconsistent model behavior can remain hidden until they create operational or business risks.

An internship becomes truly meaningful when it provides more than learning opportunities—it gives individuals the chance to contribute, take ownership, and solve real business challenges.

At Healthark, interns work on live engagements that encourage collaboration, critical thinking, and hands-on problem-solving. Rather than observing from the sidelines, they are trusted to contribute to meaningful projects while receiving continuous mentorship and guidance from experienced professionals.

In this video, our interns share how these experiences helped them strengthen their analytical thinking, communicate ideas with greater confidence, and develop a structured approach to tackling complex business problems. The journey extends beyond building technical and professional skills—it also fosters confidence, adaptability, and a deeper understanding of how real-world challenges are addressed.

A successful AI demo is only the beginning. While many healthcare AI models perform well in controlled pilot environments, the real challenge begins when they are deployed into production, where they must operate reliably within complex clinical workflows, live data environments, and strict regulatory requirements.

Many healthcare AI initiatives never progress beyond the pilot stage because production demands far more than model performance. Validation, continuous monitoring, traceability, integration with existing systems, and governance all play a critical role in ensuring AI delivers safe and consistent outcomes. In healthcare, where accuracy and reliability directly impact patient care, these requirements become even more important.

This is where LLMOps makes the difference. By enabling continuous evaluation, drift monitoring, retrieval grounding, audit trails, and human oversight, LLMOps helps organizations bridge the gap between promising AI pilots and production-ready systems.

Synthetic data is becoming an essential component of real-world evidence (RWE), enabling healthcare organizations to accelerate research while protecting patient privacy. However, as its adoption grows, so do the challenges of maintaining data integrity, regulatory compliance, and trust.

One of the most significant emerging risks is "zombie data"—synthetic or imputed records with unclear provenance that can weaken AI models, compromise research quality, and create compliance concerns. Without strong governance, organizations may struggle to verify data lineage, assess re-identification risks, and meet evolving regulatory expectations from frameworks such as the European Health Data Space (EHDS), FDA, and EMA.

Effective synthetic data governance requires more than de-identification. It depends on verifiable data provenance, rigorous privacy assessments, secure processing environments, and continuous oversight throughout the data lifecycle. By implementing these practices, healthcare and life sciences organizations can strengthen data quality, improve AI reliability, and ensure that real-world evidence remains accurate, secure, and compliant.

Professional growth is often shaped by opportunities to work across functions, collaborate with experienced leaders, and contribute to initiatives that create meaningful business impact.

In this video, Shivang Bhagat, Manager, Growth Advisory at Healthark, reflects on a three-year engagement that combined strategic planning with execution support. Working alongside senior leadership while collaborating across business development, commercial, regulatory, legal, and compliance teams provided valuable exposure to how organizations align diverse priorities to achieve shared business objectives.

These experiences go beyond individual projects. They help develop a broader understanding of decision-making, stakeholder collaboration, and the practical challenges involved in translating strategy into execution.

Real-world evidence depends on accurate and consistent healthcare data, yet some of the most damaging issues are the hardest to detect. Silent data failures occur when healthcare data pipelines continue to function normally while the meaning of the data changes in the background, often without triggering any technical errors.

One common example is the transition from ICD-9 to ICD-10 coding. Although data continues to flow without interruption, changes in coding formats can distort patient cohorts, alter disease trends, and compromise research findings if they go unnoticed. Traditional pipeline monitoring may confirm that data has arrived, but it cannot always detect whether the data still represents the same clinical meaning.

This is where anomaly detection and data observability become essential. By continuously monitoring data freshness, volume, distribution, schema, and lineage, organizations can identify unexpected changes early, investigate the cause, and restore data quality before research is affected.

Effective HCP engagement is no longer driven by CRM alone. It depends on how well organizations connect commercial, marketing, and medical functions to deliver consistent and meaningful interactions.

In Episode 3 of Marketing Minds, we explore how Veeva Systems evolved from a CRM provider into a platform that supports connected HCP engagement across pharma. By integrating physician interactions, content, workflows, and AI-powered capabilities, Veeva has helped organizations move beyond simply recording engagements to making more informed and coordinated decisions.

The discussion also highlights a challenge that continues to shape the industry today. Despite advances in technology, many organizations still struggle with fragmented engagement, inconsistent content utilization, and gaps between insight generation and execution.

Artificial intelligence is entering a new phase of innovation. For years, AI development focused on building larger models, faster processing, and more accurate responses. While these advancements have transformed healthcare, many AI systems still face challenges with multi-step workflows, long-term planning, and coordinating actions across complex environments.

The next evolution is Agentic AI—AI designed not only to respond, but to act. Instead of relying on a single model, Agentic AI brings together multiple specialized agents that collaborate toward a shared objective. These systems can adapt to changing conditions, coordinate across workflows, and support more effective decision-making in complex healthcare environments.

Healthcare is adopting AI at nearly twice the pace of the broader economy, making it one of the leading sectors driving this transformation. As organizations manage increasingly complex data and operational processes, Agentic AI has the potential to improve efficiency, strengthen collaboration, and deliver better outcomes across healthcare and life sciences.

Meaningful work is often defined by the challenges we take on, the impact we create, and the people we collaborate with along the way.

In this video, Dipesh Nagar, Manager, Growth Advisory at Healthark, shares what motivates him most about being part of the organization. From working across diverse #Healthcare engagements to collaborating with experienced colleagues, he reflects on how continuous learning and shared knowledge have shaped his professional journey.

At Healthark, teams are encouraged to step beyond conventional roles, solve complex business challenges, and contribute across a wide range of #LifeSciences engagements. This collaborative environment empowers individuals to take ownership, expand their capabilities, and grow through #Collaboration, #ContinuousLearning, and real-world experiences.

From working across a diverse range of engagements to collaborating with senior stakeholders early in his career, Shivang shares how exposure to meaningful responsibilities helped accelerate his learning and broaden his perspective. His journey highlights the value of an environment that encourages individuals to take ownership, contribute beyond their immediate roles, and continuously build new capabilities.

At Healthark, professional development goes beyond formal learning. Teams are empowered to take initiative, collaborate across functions, and learn directly from experienced leaders while working on impactful projects. This culture of ownership, collaboration, and continuous growth helps individuals develop both professionally and personally.

RISE Health Innovation Summit 2026 marks the next chapter in a journey that began with a focus on real-world evidence and has grown into a broader platform for healthcare innovation.

What started in 2024 as the RWE Summit has evolved into a global gathering designed to bring together diverse disciplines across health sciences, research, technology, data, and innovation. Over two successful editions, the summit welcomed more than 3,100 registrations, featured 62 industry speakers, and attracted participants from 14 countries, demonstrating the growing demand for deeper collaboration and broader conversations across the healthcare ecosystem.

In 2026, RISE expands its vision with a larger scope, greater ambition, and new opportunities for engagement. For the first time, the summit will feature a live event in Hyderabad alongside its virtual experience, creating a platform where experts, innovators, researchers, and industry leaders can connect, exchange ideas, and explore the future of healthcare together.

As AI becomes increasingly embedded in healthcare and life sciences, regulatory expectations are evolving alongside it. The FDA is placing greater emphasis on how AI systems influence evidence generation, clinical research, and regulatory decision-making, recognizing that not all AI applications carry the same level of risk.

Recent guidance highlights a risk-based approach, where AI tools are evaluated according to their impact on regulatory submissions and the evidence used to support critical decisions. AI systems that directly generate or influence submission evidence face the highest level of scrutiny, while operational and internal applications are subject to proportionate requirements.

The FDA is also leveraging AI within its own processes, including the deployment of generative AI tools to help accelerate application reviews. At the same time, organizations are expected to demonstrate transparency, governance, and accountability in how AI models are developed, validated, and used.

Some of the most valuable real-world insights in healthcare continue to exist within unstructured clinical records, creating both challenges and opportunities for healthcare organizations. Recent advancements in AI are transforming how this information is captured, analyzed, and utilized, enabling organizations to generate more comprehensive real-world evidence (RWE).

Research shows that AI reading raw medical records identified 207% more distinct cancer drugs than structured data alone, highlighting the significant value hidden within unstructured sources. Language models have also matched expert human reviewers on accuracy across 14 cancer types, demonstrating the growing reliability of AI-powered data extraction.

The impact extends further, with cancer therapies being captured for 65% of patients compared to 40% from structured fields. In addition, purpose-built extractors achieved roughly 95% precision and recall on key fields, supporting more accurate and scalable evidence generation.

HCP Engagement Trends 2025: The Data Pharma Marketers Can't Ignore New data on HCP engagement is exposing a widening gap between how physicians want to be reached and how pharma marketing teams are actually engaging them. According to the Veeva Pulse Field Trends Report, physician access has dropped sharply only 45% of HCPs in the US are now accessible to biopharma, down from 60% just eighteen months ago. At the same time, 50% of accessible HCPs are limiting engagement to three or fewer pharma companies, making every touchpoint far more competitive.

The real opportunity lies in content. Despite content-driven engagement being proven to double treatment adoption, only 48% of HCP meetings currently use content effectively. When relevant content is used, engagement becomes twice as effective at driving adoption compared to interactions without it.